DOI: 10.25881/20728255_2026_21_4_S1_110

Authors

Nezhuvaka I.A., Nechkina T.N., Fayzrakhmanov R.R., Shishkin M.M.

Pirogov National Medical and Surgical Center, Moscow

Abstract

Aim. To analyze the common pathogenetic mechanisms of diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA), as well as to evaluate the limitations of existing anti-VEGF therapy and the prospects of drugs targeting open pathways of the arachidonic acid cascade, interleukins, and ferroptosis.

Materials and Methods. A comprehensive analysis of Russian and international scientific publications indexed in PubMed, Scopus, and eLIBRARY.RU was conducted. The review includes data from clinical trials of novel drugs (Tonabersat, Vamikibart, K8, RC28-E, etc.).

Results. The literature analysis revealed that no existing drug completely blocks the arachidonic acid cascade. Anti-VEGF agents do not affect the 5-LOX pathway or the FGF pathway, nor do they break the vicious cycle of VEGF → COX-2 → VEGF. This explains treatment resistance and residual edema in a subset of patients. The review discusses new targets: the NLRP3 inflammasome, interleukin-6 (IL-6), and the mechanism of ferroptosis underlying GA.

Conclusions. Understanding the multi-level nature of pathogenesis justifies the need for combined blockade of mediators at different levels (from PLA2 to IL-6 and ferroptosis). Novel drugs, such as inflammasome inhibitors and anti-IL-6 agents, represent a promising direction for overcoming resistance to existing therapy.

Keywords: diabetic macular edema, retinal vein occlusion, geographic atrophy, arachidonic acid cascade, VEGF, interleukins, ferroptosis, NLRP3.

References

1. Regillo CD, et al. Predictors of anti-VEGF treatment response in diabetic macular edema. Ophthalmology. 2020; 127(9): 1203-1214.

2. Bressler NM, et al. Persistent macular edema despite anti-VEGF therapy: incidence and risk factors. Retina. 2019; 39(6): 1055-1063.

3. Campochiaro PA, et al. Long-term outcomes of anti-VEGF therapy for retinal vein occlusion. Ophthalmology. 2018; 125(6): 869-878.

4. Semeraro F, et al. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015; 2015: 582060.

5. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011; 30(5): 343-358.

6. Zileuton (Zyflo) prescribing information. Cornerstone Therapeutics.

7. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev. 2006; 58(3): 375-388.

8. Miao H, et al. Interleukin-6 in diabetic macular edema: a key mediator and therapeutic target. J Ophthalmol. 2021; 2021: 6639418.

9. Azuma K, et al. Retinal pigment epithelium-specific ablation of GPx4 in adult mice recapitulates key features of geographic atrophy in age-related macular degeneration. Cell Death Dis. 2024; 15(10).

10. Han X, et al. 5-Lipoxygenase activation induces ferroptosis in retinal pigment epithelium: implications for geographic atrophy. Oxid Med Cell Longev. 2021; 2021: 6692412.

11. Stahl A, et al. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol. 2009; 247(6): 767-773.

12. Albiñana V, et al. Etamsylate inhibits FGF-induced angiogenesis. TH Open. 2019; 3(3): e230-e243.

13. Exonate Ltd. Xiflam (Tonabersat) mechanism of action and clinical development program.

14. Tonabersat (Xiflam) Phase 2 DRCR Protocol A N trial in DME. Presented at ARVO 2026.

15. Goldberg R, et al. BARDENAS Phase 2 trial: vamikibart (anti-IL-6) in combination with ranibizumab for DME. Presented at ARVO 2026.

16. Kodiak Sciences. ALTO Phase 3 trial of KSI-501 (anti-VEGF/anti-IL-6 bispecific) in DME. Press release.

17. Inflammasome Therapeutics. K8 implant cuts lesion growth by more than 50% in geographic atrophy after 3 months. News release. September 11, 2025.

18. Sardana A, et al. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab. Indian J Ophthalmol. 2024; 72(5): 722-727.

19. Shi Y, et al. RC28-E, a bispecific antibody targeting VEGF-A and FGF-2, for diabetic macular edema: Phase 2 randomized trial. Ophthalmology. 2025.

20. VF-Trap: a dual VEGF/FGF-2 trap suppresses retinal neovascularization in the OIR model. Invest Ophthalmol Vis Sci. 2024.

21. Erdafitinib suppresses pathological retinal neovascularization via dual FGFR/VEGFR2 inhibition in the OIR model. Sci Rep. 2025.

22. Pemigatinib-associated retinopathy: subretinal fluid and RPE detachment in FGFR-mutant cancer patients. Ophthalmol Retina. 2024.

23. Fayzrakhmanov RR, Shishkin MM, Pavlovsky OA, Brechka EA, Martynov AA. Pathogenetic biomarkers of diabetic macular edema and prospects for their assessment in personalized therapy (literature review). Point of View. East–West. 2026; 13(2): 95-104. (In Russ.)

24. Chekhonin ES, Fayzrakhmanov RR, Shishkin MM, Kalanov MR. Anti-VEGF in the treatment of proliferative diabetic retinopathy (review). Saratov Journal of Medical Scientific Research. 2022; 18(3): 304–309. (In Russ.)

25. Bikbov MM, Fayzrakhmanov RR, Mavlieva VF. Analysis of structural parameters of the macular area and optic nerve head using swept-source technologies in patients with central retinal vein occlusion. Russian Ophthalmology Online. (In Russ.)

26. Fayzrakhmanov RR, Klev VS, Shishkin MM, Pavlovsky OA, Sekhina OL, Vaganova EE. Retinal detachment with macular involvement: in the struggle for maximal visual acuity. Part 1. Ophthalmology Journal. 2025; 18(1): 95-104. (In Russ.)

For citation

Nezhuvaka I.A., Nechkina T.N., Fayzrakhmanov R.R., Shishkin M.M. Common pathogenetic mechanisms of diabetic macular edema, retinal vein occlusion, and geographic atrophy: chronic inflammation and limitations of arachidonic acid cascade blockade. Bulletin of Pirogov National Medical & Surgical Center. 2026;21(4,supplement):110-115. (In Russ.) https://doi.org/10.25881/20728255_2026_21_4_S1_110